Consio | $3,300,000 | (Jan 27, 2026)
Orbital(US) | $60,000,000 | (Jan 27, 2026)
Inferact | $150,000,000 | (Jan 27, 2026)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Visitt | $22,000,000 | (Jan 27, 2026)
Cashmere(US) | $5,000,000 | (Jan 27, 2026)
Barnwell Bio | $6,000,000 | (Jan 27, 2026)
Mine(US) | $14,000,000 | (Jan 27, 2026)
Lucend | $3,300,000 | (Jan 27, 2026)
Standard Nuclear | $140,000,000 | (Jan 27, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)